Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

PharmNovo submits CTA for neuropathic pain drug candidate

PharmNovo has submitted a clinical trial application (CTA) to the Swedish Medical Products Agency and Ethical Review Authority to start a phase I study of its neuropathic pain drug candidate PN6047. The company's preclinical program has been completed with good results regarding safety and efficiency. The drug candidate is thus ready to be tested in a first-in-human study.Neuropathic pain, or nerve pain, affects nearly ten percent of the population in Europe and the United States. It is a difficult-to-treat form of pain that often develops into a chronic condition and significantly impairs

The subscription period in Alzinova’s rights issue starts today

Today, on 30 May 2022, the subscription period begins for Alzinova AB’s (publ) (“Alzinova” or the “Company”) rights issue of unit consisting of shares and warrants, which was announced on 19 April 2022 (the “Rights Issue”). The subscription period in the Rights Issue runs up to and including 13 June 2022. However, please note that nominees may have a deadline for subscription in the Rights Issue that falls before 13 June 2022.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA,

Notice to the Annual General Meeting of Loudspring Plc

Loudspring Plc Company Release                                     30 May 2022 at 9.00 (EET) Notice to the Annual General Meeting of Loudspring Plc Notice is given to the shareholders of Loudspring Plc to the Annual General Meeting to be held on Monday, 20 June 2022 at 10.00 (EET) at Radisson Blu Royal, address Runebergikatu 1, 00100 Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 9.30 (EET). A. Matters on the agenda of the Annual General Meeting At the Annual General Meeting, the

Aiforia Technologies Plc: Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies Plc Company Release 30 May 2022 09.00 a.m. EEST Aiforia Technologies Plc — Managers’ Transactions_______________________________________________   Person subject to the notification requirement   Name: Tapaninen, Jukka   Position: Chief Executive Officer   Issuer: Aiforia Technologies Plc   LEI: 743700TJRVBX7420Y723   Notification type: INITIAL NOTIFICATION   Reference number: 15589/5/4   _______________________________________________   Transaction date: 25.5.2022   Venue: FIRST NORTH GROWTH MARKET

Presentation of Biomarker Analysis at ASCO

Faron Pharmaceuticals Ltd (“Faron or Company”)   Faron Announces Presentation of Biomarker Analysis at 2022 ASCO Annual Meeting Showing PromisingClinical Benefit of Bexmarilimab in Patients with Low PD-L1 and High Clever-1 Levels   · Biomarker analyses indicate that the tumors of patients benefitting from treatment with bexmarilimab had: · statistically significant higher levels of Clever-1 positive intra-tumoral cells · low PD-L1 levels, a population that does not typically respond to or is ineligible for treatment with currently approved checkpoint inhibitors

SBB sells a development property for approximately SEK 55 million to Järngrinden

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has sold a property in Borås for an agreed property value of approximately SEK 55 million to the property company Järngrinden. The property being sold is a development property / building rights. For further information, please contact:Oscar Lekander, Deputy CEO and Chief Operating Officer, Samhällsbyggnadsbolaget i Norden AB, oscar@sbbnorden.se

Norway Royal Salmon ASA to proceed with the acquisition of SalmoNor AS and merge with SalMar ASA

Trondheim, 30 May 2022 · Norway Royal Salmon ASA (“NRS”) and SalMar ASA (“SalMar”) (“the Parties”) have entered into a merger plan whereby the two entities will merge, with SalMar as the acquiring company in the merger (the “Merger”). · The agreed exchange ratio is based on the average volume weighted closing share price of SalMar from 4 April to 20 May 2022. Based on an exchange ratio of 0.369 shares in SalMar per share in NRS, this results in a value of NOK 265.18 per NRS share, which gives a premium of 6.3% to the NRS closing price Friday 27 May 2022, and 12.1% to NRS’ average

EG7 executive team and select board members purchase additional company stock

On May 25, 2022, the EG7 executive team and select board members purchased 2,446,592 shares, representing 2.8% of outstanding shares, from Robin Flodin, the former CEO of EG7. The purchase price was SEK 16.25 per share and amounted to almost SEK 40 million. After this transaction, Mr. Flodin will no longer be a shareholder in the company. The purchasing group was led by Jason Epstein, a current board member and the proposed new chairman of the board who acquired 1.1 million shares; Ji Ham, the acting CEO, acquired 900,000 shares, doubling his stake; and Alexander Albedj, the current

Skanska redevelops army vehicle storage facility in the West of England, UK, for GBP 259M, about SEK 3.2 billion

Skanska has signed a contract with the Defence Infrastructure Organisation to redevelop a British Army vehicle storage and maintenance facility based in the West of England, UK. The contract is worth GBP 259M, about SEK 3.2 billion, which will be included in the order bookings for Europe for the second quarter of 2022.Skanska will deliver the construction, along with mechanical and electrical engineering services of new storage buildings, workshops and an office. It will see a complex programme of demolition of 58 buildings, construction of 12 new buildings and refurbishment of one existing

SynAct Pharma publishes Q1 2022 interim report

SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter 2022.“During the first quarter, we made important decisions regarding the continued development of AP1189 and not least secured financing for the next development phase. We have prepared to be able to start important studies in RA shortly, have been active in business development and have prepared for listing of the share on Nasdaq,” said Jeppe Øvlesen, CEO. January – March 2022 · The Group’s net sales amounted to SEK 0 (0) thousand, which is in line with expectations given the phase the

The subscription price for the exercise of warrants of series TO 3 in Dicot AB has been set to 0.29 SEK per share

Press release: Uppsala, May 29, 2022. During the fourth quarter of 2021, Dicot AB (publ) (``Dicot`` or ``the Company``) conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3 (previously also named series 2021/2022). Those who subscribed for units during the subscription period between October 12, 2021, and October 27, 2021, therefore obtained three (3) additional warrants of series TO 3 per unit subscribed. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in Dicot.

Scout Gaming Group bridge financing finalized

Scout Gaming Group has during the evening reaching an agreement with some of the major shareholders concerning a bridge financing, at market interest rate, to solve the liquidity for the coming months. The company will within the near future inform concerning the work which was initiated last week concerning capital raising going forward. For additional information, please contact:Andreas Ternström, CEOTel: +46 706 770 660E-mail: andreas.ternstrom@scoutgaminggroup.comNiklas Jönsson, CFOTel: +46 725 494 173E-mail: niklas.jonsson@scoutgaminggroup.com About Scout Gaming

RhoVac’s phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint

RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, regrets to announce today on May 29th, 2022, that its phase IIb study in prostate cancer, BRaVac, in spite of the previous positive results related to the compound, failed to demonstrate RV001 (onilcamotide) superiority over placebo in preventing progression in patients with biochemical recurrence (a rise in PSA) after curative intent therapy. Progression was defined as either a doubling of PSA, clinical recurrence, or death. RhoVac will undertake a more thorough analysis of the results, and a clear plan on how to proceed will be

$1 Psychic Reading Online: What To Expect

If you're curious about $1 psychic readings, you may be wondering what to expect. Psychic reading is a process in which a psychic reader attempts to read the energy of a person and their surroundings. This can provide insights into the past, present, and future. Most people who receive $1 psychic readings find them to be beneficial and insightful. However, it's essential to keep in mind that not all psychic readings are accurate. Go To The Best Psychic Reading Sites >>  There are a number of different factors that can influence the accuracy of

Nordea Bank Abp: Repurchase of own shares on 27.05.2022

Nordea Bank AbpStock exchange release – Changes in company’s own shares27.05.2022 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 27.05.2022 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading Number Weighted average Total cost, EUR* **venue (MIC of price / share, EUR* Code) shares **XSTO 110,504 9.81 1,083,825.13XHEL 106,353 9.80 1,042,248.76CEUX 237,034 9.80 2,323,912.64AQEU 26,052 9.81 255,691.08

Loyal Solutions announces the outcome of the exercise of warrants of series TO 1

On Wednesday, 25 May 2022, the exercise period for Loyal Solutions A/S (“Loyal Solutions” or the “Company”) warrants of series TO 1 ended. As the subscription price in the warrant exercise for the full period has exceeded the prevailing share price, no warrants of series TO 1 have been exercised.During the period 4 May – 25 May 2022, holders of TO 1 were entitled to subscribe for shares with support of warrants. One (1) warrant entitled the holder to subscribe for one (1) new share in Loyal Solutions at a subscription price set to SEK 24.00. No warrants have been exercised, and thus no

Borr Drilling Limited - Invitation to webcast and conference call Q1 2022 results

Borr Drilling Limited (NYSE and OSE: BORR) plans to release its financial results for the first quarter 2022 on Tuesday, May 31, 2022. A conference call and webcast is scheduled for 15:00 CET (9:00 AM New York Time) and participants are encouraged to dial in 10 minutes before the start of the call.  The earnings report and presentation will be available from the Investor Relations section on www.borrdrilling.com. In order to listen to the presentation, you may do one of the following: a)    Webcast Please use the following link: www.incommuk.com/customers/online with access code:

UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 27.05.2022

United Bankers Plc NOTIFICATION   27.05.2022 at 18:30   UNITED BANKERS PLC: ACQUISITION OF OWN SHARES 27.05.2022   Date 27.05.2022  Exchange transaction Buy  Share class UNITED  Amount 143  Average price/share 14.5500 EURHighest price/share 14.5500 EURLowest price/share 14.5500 EURTotal price 2080,65 EUR        The shares held by United Bankers Plc on 27.05.2022:   UNITED 57,024         On behalf of United

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 27.05.2022

Fiskars Corporation   Stock Exchange Release 27.05.2022 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 27.05.2022   Date 27.05.2022  Exchange transaction Buy  Share class FSKRS  Amount  8,729  Average price/share 19.0124 EURHighest price/share 19.0800 EURLowest price/share 18.8200 EURTotal price 165,959.24 EUR        The shares held by Fiskars Corporation on 27.05.2022:   FSKRS 674,781       On

Press release | first quarter results 2022

The adventure travellers are coming back – second to fourth quarter 2022 bookings spell optimism for Hurtigruten GroupFrom Alaska to Galapagos, Antarctica and the Norwegian coast – all Hurtigruten Group’s ships will be in operation as of 1 June 2022 for the first time since March 2020. Not only that – the fleet will be sailing with no capacity restrictions, the forward bookings for the 12-month period from the second quarter 2022 to the first quarter 2023 is also higher compared to pre-pandemic levels. - The first quarter of 2022 was still heavily affected by the pandemic, but countries

Nordic Aqua Partners – Invitation to presentation of Q1 2022 results

Nordic Aqua Partners will release its Q1 2022 results on Thursday, June 2, 2022 at 7:00 a.m. CEST. The presentation will be made available on the company’s website and Newsweb. Ragnar Joensen, Chairman Nordic Aqua Partners, Ove Nodland, CEO Nordic Aqua Ningbo and Hjalti Hvítklett, CFO Nordic Aqua Partners, will present the results live by webcast the same day, June 2, 2022 at 10:00 a.m. CEST. The webcast can be accessed at www.nordicaquapartners.com, or with the following link:  https://attendee.gotowebinar.com/register/4489234930958188304 For further information please contact:

#22-182 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

There are no items matching the current filter
There are no more items matching the current filter
Back to top